Testing a new medication to reduce seizures in Lennox-Gastaut Syndrome

This study is testing whether a medication called clemizole HCl can help reduce seizures in people with Lennox-Gastaut Syndrome, a rare and severe form of epilepsy that typically starts in childhood. Half of the participants will receive the new medication while the other half will receive a placebo (a pill with no active ingredient), and neither the participants nor the research team will know who is receiving which treatment. After the main study ends, eligible participants will have the option to continue taking the medication for up to 3 years to see how well it works over a longer period.

Lennox-Gastaut Syndrome is a difficult-to-treat form of epilepsy where people continue having frequent seizures even when taking multiple seizure medications. This trial exists to see if the medication can provide additional help to people whose seizures are not fully controlled by their current treatments.